Gemcitabine for the treatment of metastatic breast cancer

  • Technology appraisal guidance
  • TA116
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The following company or sponsor provided a submission for this appraisal:

  • Eli Lilly and Company Ltd

The evidence review group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessment Centre: J Jones, A Takeda, SC Tan, K Cooper, E Loveman, A Clegg, N Murray (July 2006). Gemcitabine for metastatic breast cancer.

The following individuals were selected from clinical specialist and patient advocate nominations from the professional or specialist, and patient or carer groups. They gave their expert personal views on gemcitabine plus paclitaxel by providing written and/or oral evidence to the Committee. They were also invited to comment on the Appraisal Consultation Document (ACD).

  • Professor Steve Heys, Professor of Surgical Oncology, nominated by the British Association of Surgical Oncologists as a clinical specialist

  • Dr Andreas Makris, Consultant Clinical Oncologist, nominated by the Royal College of Physicians as a clinical specialist

  • Dr Mark Verrill, Consultant Medical Oncologist, nominated by the Royal College of Physicians as a clinical specialist

  • Maria Leadbeater, Nurse Specialist Secondary Breast Cancer, nominated by Breast Cancer Care as a patient expert

  • Anna Wood, Policy and Campaigns Manager, nominated by Breast Cancer Care as a patient expert.

The following organisations are consultees or commentators in this appraisal. Consultees are also invited to appeal against the Final Appraisal Determination.

Professional or specialist, and patient or carer groups:

  • Association of Cancer Physicians

  • Association of Surgeons of Great Britain and Ireland

  • British Association of Surgical Oncology

  • British Oncological Association

  • British Oncology Pharmacy Association (BOPA)

  • British Psychosocial Oncology Society (BPOS)

  • Cancer Research UK

  • Community Practitioners' and Health Visitors' Association

  • Medical Women's Federation

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians' Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • Royal College of Surgeons

  • Royal Pharmaceutical Society

  • Breakthrough Breast Cancer

  • Breast Cancer Campaign

  • Breast Cancer Care

  • Cancer Voices

  • Cancerbackup

  • Long-term Medical Conditions Alliance

  • Macmillan Cancer Relief

  • Marie Curie Cancer Care

  • National Cancer Alliance

  • National Council for Palliative Care

  • Tenovus Cancer Information Centre

Commentator organisations (without the right of appeal):

  • Board of Community Health Councils in Wales

  • British National Formulary

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • National Public Health Service for Wales

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • Baxter Healthcare Ltd

  • Bayer plc

  • Bristol-Myers Squibb Pharmaceuticals Ltd

  • Genus Pharmaceuticals

  • GlaxoSmithKline

  • Goldshield Pharmaceuticals Ltd

  • Kyowa Hakko UK Ltd

  • Mayne Pharma plc

  • Medac UK

  • Pfizer Ltd [Pharmacia]

  • Pierre Fabre Ltd

  • Roche Products Ltd

  • Sanofi-Aventis

  • Schering-Plough Ltd

  • Wyeth Pharmaceuticals

  • Cochrane Collaboration – Cochrane Breast Cancer Group

  • Institute of Cancer Research

  • MRC Clinical Trials Unit

  • National Cancer Research Institute

  • National Coordinating Centre for Health Technology Assessment

  • Southampton Health Technology Assessment Centre

  • National Collaborating Centre for Cancer